An	0	2	O
antibody	3	11	O
directed	12	20	O
against	21	28	O
PDGF	29	33	B-Gene_or_gene_product
receptor	34	42	I-Gene_or_gene_product
beta	43	47	I-Gene_or_gene_product
enhances	48	56	O
the	57	60	O
antitumor	61	70	B-Pathological_formation
and	71	74	O
the	75	78	O
anti	79	83	O
-	83	84	O
angiogenic	84	94	O
activities	95	105	O
of	106	108	O
an	109	111	O
anti	112	116	O
-	116	117	O
VEGF	117	121	B-Gene_or_gene_product
receptor	122	130	I-Gene_or_gene_product
2	131	132	I-Gene_or_gene_product
antibody	133	141	O
.	141	142	O

Platelet	144	152	B-Gene_or_gene_product
-	152	153	I-Gene_or_gene_product
derived	153	160	I-Gene_or_gene_product
growth	161	167	I-Gene_or_gene_product
factor	168	174	I-Gene_or_gene_product
(	175	176	O
PDGF	176	180	B-Gene_or_gene_product
)	180	181	O
and	182	185	O
its	186	189	O
receptors	190	199	O
(	200	201	O
PDGFR	201	206	B-Gene_or_gene_product
)	206	207	O
play	208	212	O
important	213	222	O
roles	223	228	O
in	229	231	O
tumorigenesis	232	245	O
through	246	253	O
stimulating	254	265	O
tumor	266	271	B-Pathological_formation
growth	272	278	O
and	279	282	O
promoting	283	292	O
angiogenesis	293	305	O
via	306	309	O
enhancing	310	319	O
pericyte	320	328	B-Cell
recruitment	329	340	O
and	341	344	O
vessel	345	351	B-Multi-tissue_structure
maturation	352	362	O
.	362	363	O

Here	364	368	O
we	369	371	O
produced	372	380	O
a	381	382	O
neutralizing	383	395	O
antibody	396	404	O
,	404	405	O
1B3	406	409	B-Drug_or_compound
,	409	410	O
directed	411	419	O
against	420	427	O
mouse	428	433	B-Organism
PDGFRbeta	434	443	B-Gene_or_gene_product
.	443	444	O

1B3	445	448	B-Drug_or_compound
binds	449	454	O
to	455	457	O
PDGFRbeta	458	467	B-Gene_or_gene_product
with	468	472	O
high	473	477	O
affinity	478	486	O
(	487	488	O
9x10	488	492	O
(	492	493	O
-	493	494	O
11	494	496	O
)	496	497	O
M	497	498	O
)	498	499	O
and	500	503	O
blocks	504	510	O
PDGF	511	515	B-Gene_or_gene_product
-	515	516	I-Gene_or_gene_product
BB	516	518	I-Gene_or_gene_product
from	519	523	O
binding	524	531	O
to	532	534	O
the	535	538	O
receptor	539	547	O
with	548	552	O
an	553	555	O
IC	556	558	O
(	558	559	O
50	559	561	O
)	561	562	O
of	563	565	O
approximately	566	579	O
1	580	581	O
.	581	582	O
2	582	583	O
nM	584	586	O
.	586	587	O

The	588	591	O
antibody	592	600	O
also	601	605	O
blocks	606	612	O
ligand	613	619	O
-	619	620	O
stimulated	620	630	O
activation	631	641	O
of	642	644	O
PDGFRbeta	645	654	B-Gene_or_gene_product
and	655	658	O
downstream	659	669	O
signaling	670	679	O
molecules	680	689	O
,	689	690	O
including	691	700	O
Akt	701	704	B-Gene_or_gene_product
and	705	708	O
MAPK	709	713	B-Gene_or_gene_product
p42	714	717	I-Gene_or_gene_product
/	717	718	I-Gene_or_gene_product
44	718	720	I-Gene_or_gene_product
,	720	721	O
in	722	724	O
tumor	725	730	B-Cell
cells	731	736	I-Cell
.	736	737	O

In	738	740	O
animal	741	747	O
studies	748	755	O
,	755	756	O
1B3	757	760	B-Drug_or_compound
significantly	761	774	O
enhanced	775	783	O
the	784	787	O
antitumor	788	797	B-Pathological_formation
and	798	801	O
the	802	805	O
anti	806	810	O
-	810	811	O
angiogenic	811	821	O
activities	822	832	O
of	833	835	O
DC101	836	841	B-Drug_or_compound
,	841	842	O
an	843	845	O
antibody	846	854	O
directed	855	863	O
against	864	871	O
mouse	872	877	B-Organism
vascular	878	886	B-Gene_or_gene_product
endothelial	887	898	I-Gene_or_gene_product
growth	899	905	I-Gene_or_gene_product
factor	906	912	I-Gene_or_gene_product
receptor	913	921	I-Gene_or_gene_product
2	922	923	I-Gene_or_gene_product
,	923	924	O
in	925	927	O
a	928	929	O
pancreatic	930	940	B-Pathological_formation
(	941	942	O
BxPC	942	946	B-Pathological_formation
-	946	947	I-Pathological_formation
3	947	948	I-Pathological_formation
)	948	949	O
and	950	953	O
a	954	955	O
non	956	959	B-Pathological_formation
-	959	960	I-Pathological_formation
small	960	965	I-Pathological_formation
cell	966	970	I-Pathological_formation
lung	971	975	I-Pathological_formation
(	976	977	I-Pathological_formation
NCI	977	980	I-Pathological_formation
-	980	981	I-Pathological_formation
H460	981	985	I-Pathological_formation
)	985	986	I-Pathological_formation
tumor	987	992	I-Pathological_formation
xenograft	993	1002	I-Pathological_formation
models	1003	1009	O
.	1009	1010	O

Treatment	1011	1020	O
with	1021	1025	O
the	1026	1029	O
combination	1030	1041	O
of	1042	1044	O
1B3	1045	1048	B-Drug_or_compound
and	1049	1052	O
DC101	1053	1058	B-Drug_or_compound
in	1059	1061	O
BxPC	1062	1066	B-Pathological_formation
-	1066	1067	I-Pathological_formation
3	1067	1068	I-Pathological_formation
xenograft	1069	1078	I-Pathological_formation
-	1078	1079	O
bearing	1079	1086	O
mice	1087	1091	B-Organism
resulted	1092	1100	O
in	1101	1103	O
tumor	1104	1109	B-Pathological_formation
regression	1110	1120	O
in	1121	1123	O
58	1124	1126	O
%	1126	1127	O
of	1128	1130	O
mice	1131	1135	B-Organism
compared	1136	1144	O
to	1145	1147	O
that	1148	1152	O
in	1153	1155	O
18	1156	1158	O
%	1158	1159	O
of	1160	1162	O
mice	1163	1167	B-Organism
treated	1168	1175	O
with	1176	1180	O
DC101	1181	1186	B-Drug_or_compound
alone	1187	1192	O
.	1192	1193	O

Taken	1194	1199	O
together	1200	1208	O
,	1208	1209	O
these	1210	1215	O
results	1216	1223	O
lend	1224	1228	O
great	1229	1234	O
support	1235	1242	O
to	1243	1245	O
use	1246	1249	O
PDGFRbeta	1250	1259	B-Gene_or_gene_product
antagonists	1260	1271	O
in	1272	1274	O
combinations	1275	1287	O
with	1288	1292	O
other	1293	1298	O
antitumor	1299	1308	B-Pathological_formation
and	1309	1312	O
/	1312	1313	O
or	1313	1315	O
anti	1316	1320	O
-	1320	1321	O
angiogenic	1321	1331	O
agents	1332	1338	O
in	1339	1341	O
the	1342	1345	O
treatment	1346	1355	O
of	1356	1358	O
a	1359	1360	O
variety	1361	1368	O
of	1369	1371	O
cancers	1372	1379	B-Pathological_formation
.	1379	1380	O

